ES09.03 How I Decide 1st Line Treatment Options for Metastatic NSCLC Without Driver Mutations - Balancing Efficacy, Toxicity and Cost
2019
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI